|
Report Date : |
21.09.2013 |
IDENTIFICATION DETAILS
|
Name : |
GEA PHARMA SYSTEMS AG |
|
|
|
|
Registered Office : |
Hauptstrasse 145, Bubendorf, 4416 |
|
|
|
|
Country : |
Switzerland |
|
|
|
|
Date of Incorporation : |
22.10.1959 |
|
|
|
|
Com. Reg. No.: |
CH28039177511 |
|
|
|
|
Legal Form : |
Limited Company |
|
|
|
|
Line of Business : |
Subject supplies process equipment for the manufacture of oral,
topical & parenteral dosage forms for the pharmaceutical and biotech
industries. |
|
|
|
|
No. of Employees : |
105 |
RATING & COMMENTS
|
MIRAs Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Status : |
Satisfactory |
|
Payment Behaviour : |
No Complaints |
|
Litigation : |
Clear |
NOTES:
Any query related to this report can be made
on e-mail: infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List March 31st 2013
|
Country Name |
Previous Rating (31.12.2012) |
Current Rating (31.03.2013) |
|
Switzerland |
A1 |
A1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
switzerland ECONOMIC OVERVIEW
Switzerland is a peaceful, prosperous, and modern market economy with
low unemployment, a highly skilled labor force, and a per capita GDP among the
highest in the world. Switzerland's economy benefits from a highly developed
service sector, led by financial services, and a manufacturing industry that
specializes in high-technology, knowledge-based production. Its economic and
political stability, transparent legal system, exceptional infrastructure,
efficient capital markets, and low corporate tax rates also make Switzerland
one of the world's most competitive economies. The Swiss have brought their
economic practices largely into conformity with the EU's to enhance their
international competitiveness, but some trade protectionism remains,
particularly for its small agricultural sector. The fate of the Swiss economy
is tightly linked to that of its neighbors in the euro zone, which purchases
half of all Swiss exports. The global financial crisis of 2008 and resulting
economic downturn in 2009 stalled export demand and put Switzerland in a
recession. The Swiss National Bank (SNB) during this period effectively
implemented a zero-interest rate policy to boost the economy as well as prevent
appreciation of the franc, and Switzerland's economy recovered in 2010 with
3.0% growth. The sovereign debt crises currently unfolding in neighboring
euro-zone countries pose a significant risk to Switzerland's financial
stability and are driving up demand for the Swiss franc by investors seeking a
safe-haven currency. The independent SNB has upheld its zero-interest rate
policy and conducted major market interventions to prevent further appreciation
of the Swiss franc, but parliamentarians have urged it to do more to weaken the
currency. The franc's strength has made Swiss exports less competitive and
weakened the country's growth outlook; GDP growth fell to 1.9% in 2011 and 0.8%
in 2012. Switzerland has also come under increasing pressure from individual
neighboring countries, the EU, the US, and international institutions to reform
its banking secrecy laws. Consequently, the government agreed to conform to
OECD regulations on administrative assistance in tax matters, including tax
evasion. The government has renegotiated its double taxation agreements with
numerous countries, including the US, to incorporate the OECD standard, and is
considering the possibility of imposing taxes on bank deposits held by
foreigners. These steps will have a lasting impact on Switzerland's long
history of bank secrecy.
Source : CIA
Company Name GEA Pharma Systems
AG
Company Registration Number CH28039177511
Country CH
Activity Code 282900
Activity
Description supplies process equipment for the manufacture of oral, topical &
parenteral dosage forms for the pharmaceutical and biotech industries.
Company Status Active
Latest Turnover 5,128,325,100.00
(CHF)
Activities
Activity Code 282900
Activity Description supplies process equipment for the manufacture of oral, topical &
parenteral dosage forms for the pharmaceutical and biotech industries.
Basic Information
Company Name GEA Pharma Systems
AG
Registered Company Name GEA Pharma Systems
AG
Company Registration Number CH28039177511
Country CH
Date of Company Registration 22/10/1959
Date of Starting Operations 22/10/1959
Legal Form Limited company
Company Status Active
Principal Activity Code 282900
Principal Activity Description supplies process equipment for the manufacture of oral, topical &
parenteral dosage
forms for the pharmaceutical and biotech industries
Contact Address Hauptstrasse 145,
Bubendorf, 4416
Contact Telephone Number 0619363636
Address Hauptstrasse 145,
Country CH
Telephone 0619363636
Email Addresses info@niropharma.com
Name Pascal
Aubonney
Address Blotzheim
(Fr)
Position Member
Of The Executive Board
Name François
Bubendorf
Address Ranspach-Le-Bas
(Fr)
Position Member
Of The Executive Board
Name Hanspeter
Külling
Address Ramlinsburg,
4433
Position Member
Of The Executive Board
Name Giovanna
Rebmann
Address Pratteln,
4133
Position Member
Of The Executive Board
Name Klaus
Moeller
Address Arlesheim,
4144
Position Managing
Director
Name Paulette
Haide-Mr Üller
Address Oberwil
Bl, 4104
Position Authorized
Officer
Name Ronald
Youngs
Address Binningen,
4102
Position President
Of The Board Of Directors
Name Dr. Markus
E. Bösiger
Address Uitikon
Waldegg, 8142
Position Member
Name Tom
Niels Wrensted
Address Fredensborg
Position Member
Nominal Share Capital 3.00
(CHF)
Name GEA
Process Engineering A/S
Share Percent 100.00
%
Number of Employees 105
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.62.24 |
|
UK Pound |
1 |
Rs.99.90 |
|
Euro |
1 |
Rs.84.23 |
INFORMATION DETAILS
|
Report Prepared
by : |
MNL |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General unfavourable
factors will not cause fatal effect. Satisfactory capability for payment of
interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with full
security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
---- |
NB |
New Business |
---- |
This score serves as a reference to assess
SCs credit risk and to set the amount of credit to be extended. It is
calculated from a composite of weighted scores obtained from each of the major
sections of this report. The assessed factors and their relative weights (as
indicated through %) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend (10%) Operational size
(10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.